Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Cefuroxime Axetil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCC4 | O15439 | 2/20 | 1.00 |
| ▸ | PDE4A | P27815 | 1/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 9/20 | 0.78 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.78 |
| ▸ | NR1I2 | O75469 | 4/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.78 |
| ▸ | PGR | P06401 | 1/20 | 0.78 |
| ▸ | TSHR | P16473 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 7/20 | 0.76 |
| ▸ | CTDSP1 | Q9GZU7 | 3/20 | 0.76 |
| ▸ | POLB | P06746 | 2/20 | 0.76 |
| ▸ | PKM | P14618 | 2/20 | 0.76 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.76 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.54 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.54 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | SLC22A6 | Q4U2R8 | 2/20 | 0.50 |
| ▸ | SLC22A8 | Q8TCC7 | 2/20 | 0.50 |
| ▸ | SLC22A11 | Q9NSA0 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cefuroxime Axetil SCHEMBL7767287 | 1.00 | ABCC4 (1.00) | ABCC4PDE4ATDP1HSD17B10NR1I2 | |
| Cefuroxime Axetil SCHEMBL41099 | 1.00 | ABCC4 (1.00) | ABCC4PDE4ATDP1HSD17B10NR1I2 | |
| Cefuroxime Axetil SCHEMBL721709 | 1.00 | ABCC4 (1.00) | ABCC4PDE4ATDP1HSD17B10NR1I2 | |
| Cefuroxime Axetil SCHEMBL379336 | 1.00 | ABCC4 (1.00) | ABCC4PDE4ATDP1HSD17B10NR1I2 | |
| Cefuroxime Axetil SCHEMBL10556419 | 1.00 | ABCC4 (1.00) | ABCC4PDE4ATDP1HSD17B10NR1I2 | |
| Cefuroxime Axetil SCHEMBL13575811 | 1.00 | ABCC4 (1.00) | ABCC4PDE4ATDP1HSD17B10NR1I2 | |
| Cefuroxime Axetil SCHEMBL2221553 | 0.97 | ABCC4 (0.95) | ABCC4PDE4ATDP1HSD17B10NR1I2 | |
| Cefuroxime Axetil SCHEMBL18048098 | 0.97 | ABCC4 (0.95) | ABCC4PDE4ATDP1HSD17B10NR1I2 | |
| Cefuroxime Axetil SCHEMBL2322261 | 0.97 | ABCC4 (0.94) | ABCC4PDE4ATDP1HSD17B10NR1I2 | |
| Cefuroxime Axetil SCHEMBL2322632 | 0.92 | ABCC4 (0.84) | ABCC4PDE4ATDP1HSD17B10NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0107276-B1 | NOVEL FORM OF CEFUROXIME ESTER, PROCESS FOR ITS PREPARATION AND COMPOSITION CONTAINING IT | GLAXO GROUP LIMITED (GB) | 1987-10-07 | — | — | EP | claimed |
| US-20210401851-A1 | PAR-4 AGONISTS FOR THE TREATMENT OF CANCER | CIPLA LIMITED (IN) | 2021-12-30 | — | — | US | disclosed |
| US-11129836-B2 | PAR-4 agonists for the treatment of cancer | CIPLA LIMITED (IN) | 2021-09-28 | — | — | US | disclosed |
| US-20200046721-A1 | PAR-4 AGONISTS FOR THE TREATMENT OF CANCER | CIPLA LIMITED (IN) | 2020-02-13 | — | — | US | disclosed |
| US-20170368072-A1 | PAR-4 AGONISTS FOR THE TREATMENT OF CANCER | CIPLA LIMITED (IN) | 2017-12-28 | — | — | US | disclosed |
| US-6833452-B2 | Reacting an amine salt of cefuroxime with an esterifying agent | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-21 | — | — | US | disclosed |
| US-6833452-B2 | Reacting an amine salt of cefuroxime with an esterifying agent | RANBAXY LABORATORIES LIMITED (IN) | 2004-12-21 | — | — | US | disclosed |
| CN-1447812-A | Process for producing crystalline (R, S) -cefuroxime axetil with high purity | RANBAXY LAB LTD (IN) | 2003-10-08 | — | — | CN | disclosed |
| EP-1303523-A1 | PROCESS FOR THE PREPARATION OF THE HIGHLY PURE CRYSTALLINE (R, S) - CEFUROXIME AXETIL | RANBAXY LABORATORIES, LTD. (IN) | 2003-04-23 | — | — | EP | disclosed |
| EP-1303523-A1 | PROCESS FOR THE PREPARATION OF THE HIGHLY PURE CRYSTALLINE (R, S) - CEFUROXIME AXETIL | RANBAXY LABORATORIES, LTD. (IN) | 2003-04-23 | — | — | EP | disclosed |
| US-4994567-A | Purification by recovering from solution by roller drying | GALAXO GROUP LIMITED (GB) | 1991-02-19 | — | — | US | disclosed |
| US-4994567-A | Purification by recovering from solution by roller drying | GALAXO GROUP LIMITED (GB) | 1991-02-19 | — | — | US | disclosed |
| US-4820833-A | PURIFICATION BY SPRAY DRYING PRECIPITATION, FREEZE DRYING; CEPHALOSPORINS | GLAXO GROUP LIMITED (GB) | 1989-04-11 | — | — | US | disclosed |
| US-4820833-A | PURIFICATION BY SPRAY DRYING PRECIPITATION, FREEZE DRYING; CEPHALOSPORINS | GLAXO GROUP LIMITED (GB) | 1989-04-11 | — | — | US | disclosed |
| US-4775750-A | Process for preparing sodium cefuroxime | GLAXO GROUP LIMITED (GB) | 1988-10-04 | — | — | US | disclosed |
| EP-0107276-B1 | NOVEL FORM OF CEFUROXIME ESTER, PROCESS FOR ITS PREPARATION AND COMPOSITION CONTAINING IT | GLAXO GROUP LIMITED (GB) | 1987-10-07 | — | — | EP | disclosed |
| US-4562181-A | INCREASED ABSORPTION VIA THE GASTROINTESTINAL TRACT, ALLOWING FOR ORAL OR RECTAL ADMINISTRATION | GLAXO GROUP LIMITED (GB) | 1985-12-31 | — | — | US | disclosed |
| US-4562181-A | INCREASED ABSORPTION VIA THE GASTROINTESTINAL TRACT, ALLOWING FOR ORAL OR RECTAL ADMINISTRATION | GLAXO GROUP LIMITED (GB) | 1985-12-31 | — | — | US | disclosed |
| EP-0107276-A2 | Novel form of cefuroxime ester, process for its preparation and composition containing it | GLAXO GROUP LIMITED (GB) | 1984-05-02 | — | — | EP | disclosed |
| EP-0107276-A2 | Novel form of cefuroxime ester, process for its preparation and composition containing it | GLAXO GROUP LIMITED (GB) | 1984-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210401851-A1 | PAR-4 AGONISTS FOR THE TREATMENT OF CANCER | F2RL3, F2R, F2RL1 | ABCC4 1003/4885PDE4A 51/4885TDP1 1489/4885 |
| US-11129836-B2 | PAR-4 agonists for the treatment of cancer | F2RL3, F2R, F2RL1 | ABCC4 1003/4885PDE4A 51/4885TDP1 1489/4885 |
| US-20200046721-A1 | PAR-4 AGONISTS FOR THE TREATMENT OF CANCER | F2RL3, F2R, F2RL1 | ABCC4 1003/4885PDE4A 51/4885TDP1 1489/4885 |
| US-20170368072-A1 | PAR-4 AGONISTS FOR THE TREATMENT OF CANCER | F2RL3, F2R, F2RL1 | ABCC4 1003/4885PDE4A 51/4885TDP1 1489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.